Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

AKR1B10 (aldo-keto reductase family 1 B10) gene protein as breast cancer diagnostic marker and drug target

A diagnostic marker, breast cancer technology, applied in the field of medical biology, can solve the problem of not directly guiding treatment or indicating the sensitivity of chemotherapy drugs

Inactive Publication Date: 2012-02-08
JILIN UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Pathological diagnostic markers such as ER, PR, and HER2 are used for pathological classification of breast cancer and guiding clinical treatment. In addition, Ki-67, p53, p63, E-cadherin, etc. are also used as diagnostic markers for breast cancer, but these Independent diagnostic markers do not directly guide treatment or indicate chemotherapeutic drug sensitivity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • AKR1B10 (aldo-keto reductase family 1 B10) gene protein as breast cancer diagnostic marker and drug target
  • AKR1B10 (aldo-keto reductase family 1 B10) gene protein as breast cancer diagnostic marker and drug target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] In view of the fact that the expression of the AKR1B10 gene protein in breast ductal carcinoma in situ is positively correlated with the expression of HER2 and negatively correlated with the expression of ER, the application of this gene protein can be made into a diagnostic preparation for breast cancer through conventional technical means; it can also be used clinically It is used for pathological diagnosis and prognosis assessment of breast ductal carcinoma in situ, and can also be used as a potential target for breast cancer treatment. For specific drug preparation, please refer to the preparation method of related dosage forms of aldose reductase inhibitors such as torristat.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of an AKR1B10 (aldo-keto reductase family 1 B10) gene protein as a breast cancer diagnostic marker and a drug target, and discloses an AKR1 B10 gene protein as a diagnostic marker of HER2 (human epidermal growth factor receptor 2) high expression breast cancer and a drug target for the pathologic diagnosis and therapeutic target of breast cancer. The expression of the AKR1 B10 gene protein in ductal carcinoma in situ (DCIS) of breast is in positive correlation with HER2 expression and is in negative correlation with ER (estrogen receptor) expression.

Description

technical field [0001] The present invention relates to new pathological diagnostic markers and drug targets for ductal carcinoma in situ of the breast, especially provides the use of the AKR1B10 gene protein as a diagnostic marker for breast cancer, which can be used clinically for the pathological diagnosis and treatment of ductal carcinoma in situ of the breast. Assessing prognosis and also serving as a potential target for breast cancer treatment belongs to the field of medical biotechnology. Background technique [0002] Breast cancer is one of the malignant tumors that threaten women's lives. The recurrence rate after surgical resection at the stage of breast cancer in situ is significantly lower than that of breast cancer when it develops into invasive cancer, so diagnosis and treatment at the stage of carcinoma in situ will greatly reduce the patient's risk of death fatality rate. Most invasive carcinomas develop from ductal carcinoma in situ. To study the markers o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
Inventor 张西臣李泽中李建华何鑫张伟红邢沈阳倪劲松宫鹏涛张楠李赫张国才杨举李淑红
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com